Clinical Trial Details
— Status: Terminated
Administrative data
NCT number |
NCT03874169 |
Other study ID # |
AAAS1510 |
Secondary ID |
|
Status |
Terminated |
Phase |
|
First received |
|
Last updated |
|
Start date |
March 29, 2019 |
Est. completion date |
July 20, 2021 |
Study information
Verified date |
April 2023 |
Source |
Columbia University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The purpose of this study to improve methods of monitoring and diagnosing gastrointestinal
bleeding via the E4 wristband, a biosensor watch.
Description:
The annual occurrence of gastrointestinal (GI) bleeding is approximately 150 per 100,000 in
the US and accounts for 300,000 hospitalizations per year with a death rate of 5%.
Qualitative assessments of blood tests monitoring patients with or are thought to have GI
bleeding can lack accuracy and objectivity, delaying conformation of the bleed through
endoscopy. Early endoscopies have been linked to more favorable outcomes for patients with
heavier GI bleeding and earlier discharge times for patients with less severe GI bleeding.
Additionally, laboratory values are not documented at regular intervals, which makes
identifying when GI bleeding exactly occurred difficult. In this study, the investigators aim
to improve methods of monitoring and diagnosing GI bleeding via the E4 wristband, a biosensor
watch. Using data from the E4 wristband, the investigators will train a model to recognize GI
bleeding through analyzing the heart rate and skin conductance of both patients with GI
bleeding and who may have GI bleeding while they are not bleeding and while they are
bleeding. Monitoring both types of patients while they are and are not bleeding will help the
model discern which vital signs are critical. Additionally, the investigators will be using
blood tests and other traditional methods of diagnosis to create a standard for vitals that
characterize GI bleeding. If the E4 wristband is successfully able to accurately identify
when a patient is experiencing GI bleeding, then speed of GI bleeding detection and the
ability to monitor GI bleeding will dramatically increase, leading to quicker discharge
times, reduced risk of rebleeding, and a lower death rate for afflicted patients.